Spyre Therapeutics, Inc. SYRE Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s operating income?
- Spyre Therapeutics, Inc. (SYRE) reported operating income of -$45.64M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s operating income changed year-over-year?
- Spyre Therapeutics, Inc.'s operating income increased by 14.8% year-over-year, from -$53.57M to -$45.64M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s operating income has grown at a 33.7% compound annual growth rate (CAGR), from -$65.65M to -$209.56M.
- What does operating income mean?
- Operating income is the profit or loss generated from core business operations, calculated by subtracting total operating expenses from gross profit. It excludes interest, taxes, and non-operating items, providing a measure of how effectively the company manages its primary business activities. For early-stage biotech, this is typically negative due to heavy R&D investment.